A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients

Table 2

Percentages of MDSCs subpopulations in NSCLC patients.

(a) Published subpopulations

MDSC subpopulations (%) (parental gate)	NSCLC patients ( = 110)
	Mean ± SEM	Range	Median
CD33^+ CD11b^+ (in CD11b^+)	41.41 ± 2.9	0.2–97.9	40.80
G-MDSC
CD14^−CD11b^+ (lymphocytes excluded)	66.07 ± 3.0	0.7–99.9	74.70
CD14^−CD11b^+CD33^+ (in CD14^−CD11b^+)	83.25 ± 2.3	3.6–99.9	93.65
CD14^−CD15^+CD33^+CD11b^+ (in CD14^−CD15^+)	40.27 ± 3.1	0.1–97.3	40.40
M-MDSC
CD14^+HLA-DR^−/low (in CD14^+)	25.2 ± 2.1	0.8–83.2	19.01

(b) New subpopulations

MDSC subpopulations (%) (parental gate)	NSCLC patients ( = 110)
	Mean ± SEM	Range	Median
G-MDSC
CD14^−CD15^+CD33^+CD11b^+HLA-DR^−Lin^− (in CD14^−CD15^+)	1.97 ± 0.5	0–44	0.65
M-MDSC
CD14^+CD15^+CD33^+CD11b^+HLA-DR^−Lin^− (in CD14^+CD15^+)	3.55 ± 0.5	0–42	2.10
CD14^+CD15^−CD33^+CD11b^+HLA-DR^−Lin^− (in CD14^+CD15^−)	5.21 ± 0.5	0–21	3.15

M-MDSC: Monocytic Myeloid-Derived Suppressor cells; G-MDSC: Granulocytic Myeloid-Derived Suppressor cells.